Abstract
A total of 16 targeted NO-releasing betulinic acid (BA) derivatives were designed and synthesized as potential anticancer agents. Most IC50 values were under 1.0 μM in vitro test against HepG2 and B16. The result suggested that derivatives of BA with α,β-unsaturated ketone skeleton possessed significant cytotoxic activities than the others, among which derivatives with three carbons in diol linker (15b and 15c) exhibited the highest anti-cancer activity. NO-releasing amount detection of partial target compounds suggested that NO-releasing amount of this series of BA derivatives positively correlates with their cytotoxic activities. The anti-angiogenic activity of partial target compounds on zebrafish embryos in our experiment did not show any effects on the SIVs, however, they exhibited different influence on ISVs, with only 15a and 15d better than the negative control.
Keywords: Betulinic acid derivatives, cytotoxic activities, NO-releasing, anti-angiogenic activity.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Design and Synthesis of NO-releasing Betulinic Acid Derivatives as Potential Anticancer Agents
Volume: 17 Issue: 2
Author(s): Jinhong Liu, Zifei Zhu, Jia Tang, Qinghua Lin, Li Chen and Jianbo Sun
Affiliation:
Keywords: Betulinic acid derivatives, cytotoxic activities, NO-releasing, anti-angiogenic activity.
Abstract: A total of 16 targeted NO-releasing betulinic acid (BA) derivatives were designed and synthesized as potential anticancer agents. Most IC50 values were under 1.0 μM in vitro test against HepG2 and B16. The result suggested that derivatives of BA with α,β-unsaturated ketone skeleton possessed significant cytotoxic activities than the others, among which derivatives with three carbons in diol linker (15b and 15c) exhibited the highest anti-cancer activity. NO-releasing amount detection of partial target compounds suggested that NO-releasing amount of this series of BA derivatives positively correlates with their cytotoxic activities. The anti-angiogenic activity of partial target compounds on zebrafish embryos in our experiment did not show any effects on the SIVs, however, they exhibited different influence on ISVs, with only 15a and 15d better than the negative control.
Export Options
About this article
Cite this article as:
Liu Jinhong, Zhu Zifei, Tang Jia, Lin Qinghua, Chen Li and Sun Jianbo, Design and Synthesis of NO-releasing Betulinic Acid Derivatives as Potential Anticancer Agents, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (2) . https://dx.doi.org/10.2174/1871520616666160926115747
DOI https://dx.doi.org/10.2174/1871520616666160926115747 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genetic and Pharmacological Modulation of Dendritic Cell-T Cell Interactions as a Therapeutic Strategy for Systemic Lupus Erythematosus
Current Gene Therapy Adalimumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Allosteric Modulators for Adenosine Receptors: An Alternative to the Orthosteric Ligands
Current Topics in Medicinal Chemistry Challenges and Persistent Questions in the Treatment of Trichomoniasis
Current Topics in Medicinal Chemistry Recent Patents on Common Modifications Made to Traditional Micellar- Based Chemotherapeutics Designed to Improve Drug Delivery
Recent Patents on Nanomedicine Carotenoids and Cardiovascular Risk
Current Pharmaceutical Design The Role of Connexins in Carcinogenesis: Review of Current Knowledge
Current Signal Transduction Therapy Hybrid Imidazole-Pyridine Derivatives: An Approach to Novel Anticancer DNA Intercalators
Current Medicinal Chemistry The PI3K/Akt Pathway: Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors
Current Cancer Drug Targets Tumor Intracellular Redox Status and Drug Resistance-Serendipity or a Causal Relationship?
Current Pharmaceutical Design Thalidomide: A Banned Drug Resurged into Future Anticancer Drug
Current Drug Therapy A Systematic SAR Study of C10 Modified Paclitaxel Analogues Using a Combinatorial Approach
Combinatorial Chemistry & High Throughput Screening Advances in Drug Safety
Current Pharmaceutical Design Tailoring NO Donors Metallopharmaceuticals: Ruthenium Nitrosyl Ammines and Aliphatic Tetraazamacrocycles
Current Medicinal Chemistry Single Nucleotide Polymorphisms as the Efficient Prognostic Markers in Breast Cancer
Current Cancer Drug Targets Gene Expression Abnormalities in Thymoma
Current Pharmacogenomics Potentials of Polymeric Nanoparticle as Drug Carrier for Cancer Therapy: With a Special Reference to Pharmacokinetic Parameters
Current Drug Metabolism Natural Products Inhibiting the Ubiquitin-Proteasome Proteolytic Pathway, A Target for Drug Development
Current Medicinal Chemistry Advancement Towards Tin-based Anticancer Chemotherapeutics: Structural Modification and Computer Modeling Approach to Drug-Enzyme Interactions
Current Topics in Medicinal Chemistry Radiation Induced Non-targeted Response: Mechanism and Potential Clinical Implications
Current Molecular Pharmacology